Aethlon Medical Inc AEMD.OQ AEMD.O is expected to show no change in quarterly revenue when it reports results on August 13 for the period ending June 30 2025
LSEG's mean analyst estimate for Aethlon Medical Inc is for a loss of 86 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 2.9% in the last three months.
Wall Street's median 12-month price target for Aethlon Medical Inc is $3.03, about 59.3% above its last closing price of $1.23
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.98 | -1.01 | -7.97 | Missed | -689.1 |
Dec. 31 2025 | -1.68 | -1.71 | -1.04 | Beat | 39.1 |
Sep. 30 2024 | -1.60 | -1.56 | -1.60 | Missed | -2.6 |
Jun. 30 2024 | -2.45 | -2.52 | -2.72 | Missed | -7.9 |
Mar. 31 2024 | -11.28 | -9.84 | -7.28 | Beat | 26 |
Dec. 31 2023 | -9.84 | -9.84 | -10.96 | Missed | -11.4 |
Sep. 30 2023 | -10.40 | -11.20 | -9.76 | Beat | 12.9 |
Jun. 30 2023 | -9.60 | -10.40 | -11.20 | Missed | -7.7 |
This summary was machine generated August 11 at 21:07 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)